Oil-in-water nanoemulsions for glaucoma treatment: An insight into the latest trends

Ankita Kishore, Alok Kumar Mahor, Niraj Kumar Singh, Prem Prakash Singh, Priyanka Rathore, Kuldeep K. Bansal

1Institute of Pharmacy, Bundelkhand University, Jhansi, India
2Division of Pharmacology, Institute of Pharmaceutical Research, GLA University, Mathura 281406, India
3Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Abo Akademi University, 20520 Turku, Finland

Introduction
Glaucoma is a group of eye conditions that damage the optic nerve, vital for transmitting visual information to the brain. Typically, the damage is due to elevated intraocular pressure (IOP), which can ultimately lead to blindness, making it the second leading cause of blindness worldwide, following cataracts. The condition is associated with various risk factors and primarily affects the optic nerve. To treat glaucoma, a range of approaches, both traditional and innovative, have been employed. Recently, there has been a significant focus on nanoemulsions as a promising avenue for treatment. This review underscores the advantages of using oil-in-water nanoemulsions for ocular drug delivery, showcasing their superiority in terms of enhanced bioavailability and stability compared with other dispersion systems. This review also delves into the limitations inherent in traditional drug formulations, elucidates the mechanisms governing drug release, explores the pivotal role of surfactants, and examines the landscape of granted patents in this domain. By addressing these critical aspects, the review offers invaluable insights into the treatment of glaucoma, shedding light on innovative approaches that hold great promise in the fight against this debilitating eye condition. During our search, it was noticed that despite the existence of commendable research in the field of ocular nanoemulsions, particularly in the context of glaucoma along with granted patents, the commercialized nanoemulsion formulations for glaucoma is not yet exist.

Abstract
Glaucoma is a serious eye disease characterized by elevated intraocular pressure, which can ultimately lead to blindness, making it the second leading cause of blindness worldwide, following cataracts. The condition is associated with various risk factors and primarily affects the optic nerve. To treat glaucoma, a range of approaches, both traditional and innovative, have been employed. Recently, there has been a significant focus on nanoemulsions as a promising avenue for treatment. This review underscores the advantages of using oil-in-water nanoemulsions for ocular drug delivery, showcasing their superiority in terms of enhanced bioavailability and stability compared with other dispersion systems. This review also delves into the limitations inherent in traditional drug formulations, elucidates the mechanisms governing drug release, explores the pivotal role of surfactants, and examines the landscape of granted patents in this domain. By addressing these critical aspects, the review offers invaluable insights into the treatment of glaucoma, shedding light on innovative approaches that hold great promise in the fight against this debilitating eye condition. During our search, it was noticed that despite the existence of commendable research in the field of ocular nanoemulsions, particularly in the context of glaucoma along with granted patents, the commercialized nanoemulsion formulations for glaucoma is not yet exist.

Keywords:
Glaucoma
Nanoemulsion
Ophthalmic
Cationic surfactants
Ostwald ripening

*Corresponding authors: Alok Kumar Mahor, Email: alokmahor522@bujhansi.ac.in; Kuldeep Kumar Bansal, Email: kuldeep.bansal@abo.fi

© 2024 The Author(s). This work is published by Biomed Research as an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited.
Two types of glaucoma can be considered as major types, (a) open-angle glaucoma, and (b) closed-angle glaucoma. The first type which is primary open-angle glaucoma (POAG) is the most common (3). A critical pathological risk factor for POAG involves intraocular pressure levels, which are produced within the anterior chamber of the eye due to resistance in draining aqueous humor from the trabecular meshwork and the inner wall of Schlemm's canal. Generally, the breadth of the angle between the cornea and iris permits normal aqueous fluid outflow from the anterior chamber to the drainage channels of the trabecular meshwork. Finally, the issue with fluid outflow was caused by the malfunction of the trabecular meshwork, which becomes blocked by cell debris, including inflammatory or blood cells. The most prevalent type of glaucoma is primary open-angle glaucoma (or POAG), which is linked to increased resistance in the aqueous outflow channels. Offten, there are no immediate or acute signs or symptoms and no discomfort. The only symptoms that worsen over time are narrowing of the visual field and alterations in the optic nerve. Secondary, closed-angle glaucoma, characterized by the narrowing or occlusion of the outflow route, hinders the drainage of aqueous fluid, potentially leading to sudden spikes in IOP and significant ocular discomfort. Another type of glaucoma is congenital glaucoma, which manifests in babies with symptoms such as excessive tearing, light sensitivity, a fear of light, and eyelid retraction. These signs are often accompanied by a noticeable enlargement and cloudiness of the cornea. The study of glaucoma and its consequences has been the focus of numerous investigations. Fig. 1 illustrates a comparison between eyes with normal and increased IOP, whereas the second comparison, shown in Fig. 2, distinguishes between open-angle and closed-angle glaucoma.

Glucoma can also be considered as a set of ocular neuropathic conditions that together account for the world's leading cause of irreversible blindness, where blindness is caused by the degeneration of neural tissues in the optic projection from the retina to the brain. Glaucoma is becoming more common as the population ages; by 2040, nearly 112 million people will be affected worldwide.

Traditional ophthalmic solutions, employed over an extended period, have limitations in terms of therapeutic effectiveness. Challenges include drug elimination...
before corneal contact, drainage influenced by gravity, nasolacrimal system drainage, absorption by the conjunctiva, and a deficiency in controlled release and bioadhesive properties. The non-adherence of patients to medications is also one of the main problems in the treatment of glaucoma. Glaucoma-induced blindness can be avoided if the disease can be diagnosed at a very early stage and by taking medications timely. Effective treatment of glaucoma requires patients to maintain good adherence and persistence in controlling their intraocular pressure. Patients must be well-informed about their condition. Improving patient adherence necessitates establishing effective communication between healthcare providers and patients and implementing long-term strategies to enhance adherence. Poor adherence often stems from factors such as forgetfulness, challenges with applying eye drops, and difficulties adhering to medication schedules.

Researchers are currently exploring novel drug delivery systems to overcome the limitations of conventional ophthalmic dosage forms and improve patient compliance. One promising system under investigation is nanoemulsions, which have the potential to overcome these limitations. Nanoemulsions are liquid dispersion systems with nanoscale phases containing oil, water, and a surfactant. Specifically, cationic oil-in-water nanoemulsions are preferred in ophthalmic applications because of their superior adherence to the ocular surface and transparent appearance. These nanoemulsions can carry hydrophobic drugs, and the inclusion of cationic surfactants enhances their ability to penetrate ocular surfaces. This resulted in improved bioavailability and extended the shelf life of the formulation. Ocular nanoemulsions are gaining attention as a promising option in the realm of novel ophthalmic drug delivery systems, particularly in glaucoma. Studies suggest that nanoemulsions loaded with anti-glaucoma drugs can effectively overcome the challenges associated with targeting drug delivery to the anterior chamber of the eye.

Thus, in this review, we embrace the applicability of oil-in-water nanoemulsions in enhancing the bioavailability of hydrophobic drugs. Furthermore, this study focuses on nanoemulsion stability, drug release, and stabilization mechanisms. Cationic nanoemulsions have additional advantages in overcoming ocular barriers. An explanation of some of these agents and their comparison has been discussed. The article also encompasses recent research conducted and granted patents in the field of nanoemulsion. Safety and toxicity considerations in formulation have been summarized based on published studies. Unlike other existing review articles, our goal was to consolidate critical information about ocular nanoemulsions in single article. We investigated the correlation between marketed ocular nanoemulsion preparations, patents granted for glaucoma, and ongoing research in ophthalmic nanoemulsions. The collected information revealed a gap in current knowledge and researchers can leverage these data to assess the current status of nanoemulsion in the field of glaucoma.

**Conventional ocular drug delivery systems used for treating glaucoma**

Ocular drug delivery systems are intended to be used in the eyes. Several drug delivery systems are available to treat various ocular problems in different parts of the eye. The following are some drug delivery systems specific to glaucoma treatment.

Numerous drugs with antiglaucoma properties are accessible, but a significant challenge lies in devising effective delivery systems that target the eye. This article is dedicated to the treatment of glaucoma and other ocular disorders using nanoemulsion-based drug-loaded delivery systems. The traditional drug delivery systems mentioned below have been utilized for the treatment of glaucoma over an extended period.

**Conventional drug delivery systems**

Numerous traditional dosage forms are commercially available and have been employed for an extended period to treat glaucoma, each operating through distinct mechanisms (Fig. 3).

**Topical solutions or eye drops**

The most practical, secure, immediately effective, patient-compliant, non-invasive, and comfortable method for administering ocular medications is topical drops. Tonicity, pH, stability, viscosity, sterility, and the choice of a preservative are the most crucial aspects to consider when making an ophthalmic solution. One study has shown that ophthalmic solutions, after opening for 30 days, can vary in pH, which is generally not statistically meaningful for the solutions.

---

**Fig. 3. Conventional drug delivery systems for treating glaucoma.**
**Topical emulsions**
The bioavailability and solubility of pharmaceuticals can be enhanced using an emulsion-based formulation strategy.\textsuperscript{41} Emulsions, especially microemulsions, appear to be rapidly moving toward commercial applications and may become the preferred delivery system for lipid-soluble ophthalmic medications.\textsuperscript{32} Ophthalmic emulsions are intricate systems used to transport medications that are poorly penetrable to the eye, which is a complicated organ with several potential target tissues, depending on the condition.\textsuperscript{33}

**Topical suspension**
Eye drops for drugs that are difficult to dissolve are commonly made as suspensions.\textsuperscript{34} The basic requirements and indications for liquid and semisolid vehicles containing dispersed drugs are the same as those for regular eye drops, ointments, and hydrogels that include dissolved medications.\textsuperscript{32}

**Topical ointments**
A blend of semisolid and solid hydrocarbons with a melting temperature at physiological ophthalmic temperature makes up ophthalmic ointments.\textsuperscript{35} Ointments aid in maintaining drug release and increasing ophthalmic bioavailability.\textsuperscript{36}

**Topical gel**
It is of two types: hydrophilic polymer-based aqueous gels (hydrogels) and stimuli-responsive polymer-based aqueous gels.\textsuperscript{37} However, this formulation has not been well received due to hazy vision.\textsuperscript{38} This problem can be solved by using an in situ gel-forming ocular drug delivery system made of polymers that demonstrate a sol-to-gel phase transition in the eyes in response to a change in a particular physiochemical parameter.\textsuperscript{39} The abovementioned conventional topical formulations were limited in their actions because of various ophthalmic barriers.\textsuperscript{40} These barriers protect the eyes from the external environment and materials, causing the externally applied drug concentration to decrease at the place of application within a few seconds. Thus the time needed for absorption of the drug was also reduced. Therefore, scientists have huge opportunities to overcome these barriers and increase the contact time of formulations on the eye surface.\textsuperscript{41}

**Solid dosage form (tablets)**
The doctor may recommend an oral tablet, typically a carbonic anhydrate inhibitor, if the above-discussed conventional topical dosage forms alone fail to reduce eye pressure to the required level.\textsuperscript{42,43} Many conventional drug delivery systems are commercially available for glaucoma, but these conventional forms have basic formulation-related limitations. Owing to these limitations, some advancements are required to enhance formulation efficacy. Therefore, we are moving toward novel drug delivery-based systems. Table 1 summarizes a few commercial formulations that are used for treating glaucoma along with their limitations.

Conventional dosage forms for treating glaucoma face some typical problems such as short time for drug retention, corneal penetration, formulation removal from eyes, and low bioavailability, that inhibit them from imparting sufficient therapeutic effect for treatment. The challenges faced in conventional dosage forms for glaucoma include the following:

A. **Limited drug retention**: Conventional eye drops face challenges in retaining the administered drug within the eye. Factors such as tear drainage, blinking, and nasolacrimal drainage contribute to reduced drug retention on the ocular surface.

B. **Ineffective corneal penetration**: The corneal epithelium with its tight junctions poses a barrier to effective drug penetration. Achieving sufficient drug levels in the cornea is challenging with conventional formulations.

C. **Short residence time**: Conventional dosage forms are prone to rapid elimination from the ocular surface, leading to a short residence time. This limits the duration of the therapeutic action.

D. **Systemic absorption**: There is a risk of systemic absorption of the drug, especially when administered through eye drops. This can lead to systemic side effects and may not be ideal for patients with certain medical conditions.

E. **Limited bioavailability**: Precorneal factors, such as tear dilution and drainage, contribute to the limited bioavailability of drugs delivered through conventional dosage forms. This may result in suboptimal therapeutic outcomes.

F. **Lack of Controlled Release**: Conventional eye drops lack controlled release mechanisms, leading to fluctuations in drug concentrations. This can affect the sustained therapeutic effect required for glaucoma management.

G. **Patient compliance**: The need for frequent administration of eye drops poses challenges related to patient compliance. Patients may forget or find it inconvenient to adhere to the prescribed dosing regimen.

H. **Bioadhesion issues**: Conventional formulations may lack sufficient bioadhesive properties, making it challenging for the drug to adhere to the ocular surface and prolong contact time.

Topical hypotensive medications are ineffective; 20% of the prescribed quantity is squandered, and each eye may require up to 3.7 drops of medication per dose. Drug waste is also a result of the ocular surface’s poor absorption capacity. Topical dosages have 1%–10% bioavailability because of the cornea’s rapid and poor absorption of the medication. IOP may be ineffectively controlled as a result, and the illness may worsen. Sustained release of novel drug delivery systems is being investigated as a potential solution to these problems.\textsuperscript{48} Addressing these challenges has led to the exploration of novel drug delivery systems, such as nanoemulsions and
other nanotechnology-based approaches, to enhance the efficacy and patient compliance in glaucoma therapy.

**Nanoemulsions: Characteristics and composition**

When two or more immiscible phases are mechanically sheared with the appropriate surfactants, at least one of the phases is dispersed in the other phases, creating a thermodynamically or kinetically stable system known as a nanoemulsion.

Nanoemulsions are unique in their composition, featuring a biocompatible, nonpolar oil phase with structural similarities to substances commonly found in the human body and food. In pharmaceutical applications, oil-in-water nanoemulsions are favored because of their ability to effectively retain lipophilic drugs within the internal phase. These nanoemulsions leverage primary and secondary surfactants, in conjunction with a high zeta potential, to generate repulsion forces among their components, thereby ensuring superior thermodynamic stability among the dispersed globules. The benefits of nanoemulsions extend beyond conventional emulsions. Notably, they offer heightened thermodynamic stability, reduced viscosity, and improved drug bioavailability because of the larger surface area of their globules. It is important to note that nanoemulsions excel in terms of biocompatibility, which sets them apart from certain nanoparticle-based systems that may pose potential toxicity risks due to the materials employed in their formulations. This exceptional compatibility is attributed to the presence of lipids and water in the nanoemulsions, making them an ideal choice for various pharmaceutical applications.

**Significance of droplet size and zeta potential in nanoemulsions**

The stability of nanoemulsion hinges on factors such as droplet size, surface charge, and emulsifier composition.

These elements collectively dictate the overall stability. A well-calibrated emulsifier blend establishes a flexible interface between immiscible liquids, effectively suspending small globules of the dispersed phase. These droplets, endowed with elasticity, can withstand high deformation levels, thereby enhancing stability. Smaller, uniformly sized droplets further fortify stability by minimizing the impact of gravitational forces. Moreover, a robust intermolecular repulsive force driven by a higher surface charge keeps smaller droplets separated. During elastic collisions, approaching droplets experience a force that propels them apart, thereby thwarting coalescence. This charge-driven repulsion mechanism sustains all charged nanodroplets in a continuous Brownian motion.

A similar charge-based repulsion mechanism stabilizes mono-surfactant-based nanoemulsions, as shown in Fig. 4, to clarify the stabilization process. The gravitational pull of the globules is determined by their mass and size, whereas the repelling force is influenced by the strength of the zeta potential. Zeta potential values can serve as predictors of the stability of nanoemulsions. The pharmacokinetics and biodistribution of nanoemulsions are similarly affected by droplet size. Reduced droplet size provides a longer blood residence time, indicating a size-dependent effect on the duration of circulation. Thus, the zeta potential and droplet size are important parameters to be considered in the case of a good nanoemulsion.

**Considerations concerning the development of ocular Nanoemulsions:**

When developing ophthalmic drug delivery systems, it is crucial to consider various barriers, challenges, and influencing factors, all of which are detailed in Table 2. These principles also apply to the development of ophthalmic nanoemulsions, making them a versatile and valuable option for enhancing drug delivery.

---

### Table 1. Commercial products and limitations of conventional ophthalmic drug delivery systems

<table>
<thead>
<tr>
<th>Conventional ophthalmic drug delivery system</th>
<th>Commercial products</th>
<th>Limitations of the conventional drug delivery system</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ophthalmic Solutions or Eye Drops</td>
<td>Alphagan solutions (brimonidine tartarate), Combigan solutions (brimonidine &amp; timolol), Lumigan solutions (bimatoprost), etc.</td>
<td>Rapid removal of the drug due to lacrimal secretions, low bioavailability, frequent instillation, quick drainage, and sustainable action.</td>
<td>44,45</td>
</tr>
<tr>
<td>Ophthalmic Emulsions</td>
<td>Xelpros (latanoprost)</td>
<td>Toxicity (greater concentration) and stability are influenced by the choice of co-surfactant, aqueous, and organic phase.</td>
<td>44</td>
</tr>
<tr>
<td>Ophthalmic Suspension</td>
<td>Azopt suspension (brinzolamide), symbrinza (brimonidine &amp; brinzolamide),</td>
<td>Irritation due to the presence of particles and loss of drug solution.</td>
<td>44</td>
</tr>
<tr>
<td>Ophthalmic Ointment</td>
<td>Lacort (Chloramphenicol &amp; Hydrocortisone)</td>
<td>Blurring vision, poor patient compliance, eyelid stickiness, and the partition coefficient restrict drug selection.</td>
<td>45</td>
</tr>
<tr>
<td>Ophthalmic Gel</td>
<td>Olopin-HS (pilocarpine HCl)</td>
<td>Only triggered by temperature, pH, and ionic strength after the use of matted eyelids, with no control on the rate of diffusion.</td>
<td>37,46</td>
</tr>
<tr>
<td>Solid dosage forms</td>
<td>Diamox (acetazolamide) and neptazane (methazolamide)</td>
<td>Blood–ocular barriers, limit drug penetration, and drug loss due to liver metabolism and kidney clearance.</td>
<td>47,48</td>
</tr>
</tbody>
</table>
Advantages of nanoemulsions in improving bioavailability and penetration of the ocular surface

Nanoemulsions play a vital role in the formulations of hydrophobic drugs, especially those of the oil-in-water type. In this configuration, oil droplets serve as carriers for hydrophobic drugs, thereby improving their bioavailability through increased surface area and penetration. However, integrating hydrophobic ocular drugs into nanoemulsions poses several challenges because of the eye’s intricate anatomy and physiology. The eye is highly sensitive to foreign substances and rapidly removes them from its surface. Additionally, the lacrimal gland consistently secretes tear fluid, accounting for approximately 16% of the total tear volume per minute under normal conditions.

The challenges in delivering drugs to the eyes create two significant issues. First, conventional aqueous eye drops are not suitable for the integration of hydrophobic drugs. Second, the eye’s drainage systems swiftly eliminates eye drops, with approximately 80% removed within minutes, demanding frequent dosing for sustained therapeutic effects. In response, nanoemulsions have emerged as promising remedies for ocular drug delivery. The Novasorb product series has effectively employed nanoemulsions.

Earlier methods aimed at boosting solubility inadvertently reduced pharmacokinetics and bioavailability while elevating toxicity levels in the system.

To make the formulation more sustainable, other secondary formulations can also be developed by using this basic nanoemulsion as its primary formulation. For example, Tau et al developed an ocular nanoemulsion for latanoprost, another hydrophobic drug. This nanoemulsion contained a mild preservative, potassium sorbate, and avoided the use of the surfactant benzalkonium chloride, which is known to cause ocular toxicity with long-term use. A comparison between this gentle nanoemulsion and an ophthalmic solution containing benzalkonium chloride revealed that the former was milder and better tolerated.

Table 2. Barriers, challenges, and consideration factors during the development of topical ocular drug delivery systems

<table>
<thead>
<tr>
<th>Ophthalmic barriers to ocular drug delivery</th>
<th>Challenges in the development of topical ocular drug delivery</th>
<th>Parameters to be considered when developing ocular drug delivery systems</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Tight junction of the corneal epithelium</td>
<td>• Absorption (&gt;5% bioavailability)</td>
<td>• Anatomical structure and functions of the eye</td>
</tr>
<tr>
<td>• Very small volume of the conjunctival sac (30 µl)</td>
<td>• Development of dosage forms of drugs with limited aqueous solubility.</td>
<td>• Tear compositions that can affect drug absorption.</td>
</tr>
<tr>
<td>• Reflex blinking of eyes (5-7 times in a minute)</td>
<td>• Ease of use (low discomfort)</td>
<td>• Presence of any other ocular diseases</td>
</tr>
<tr>
<td>• Biotransformation of drugs in ocular tissues</td>
<td>• Limited excipient availability concerning the safety of the eyes</td>
<td>• Compatibility with patient expectations</td>
</tr>
<tr>
<td>• Increased tear production</td>
<td>• Delivery of the drug to the posterior segment of the eye. (Often invasive therapy is preferred)</td>
<td>• Comfortable to the eyes</td>
</tr>
<tr>
<td>• High rate of tear fluid exchange</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• High evaporation route of the tear fluid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Corneal thickness</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Absorption through the cornea</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Absorption through the conjunctiva</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Drug-Protein binding</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Efflux pumps</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Nasolacrimal efflux</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Lymphatic clearance</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Conjunctival blood flow</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Fig. 4. Stabilization mechanism of the nanoemulsion.
**Prolonged drug release**

The process of drug release from a nanoemulsion typically consists of three distinct steps, as depicted in Fig. 5. This process is influenced by various factors, including the components of the formulation, the characteristics of the active pharmaceutical ingredients, and the surrounding environmental conditions. The steps of drug release can be described as follows:

a) Initially, the drug transitions from the oil phase to the surfactant layer and subsequently into the aqueous phase (the mucous layer of the tear film is hydrophilic) during drug release from the nanoemulsion.

b) As the solubilized portion of the drug moves out of the oil phase and encounters the surrounding water, nanoprecipitation occurs. This nanoprecipitation event results in a significant increase in the drug's surface area, consequently expediting its disintegration, as described by the Noye–Whitney equation.

Additionally, nanoemulsions frequently require less surfactant than conventional colloidal dispersions while preserving many benefits and are thus anticipated to overwhelm the commercial drug delivery barrage.

The nanoemulsion becomes unstable because of the shift in droplet size caused by Ostwald ripening. Stabilizing the oil-water interface during emulsification is a major challenge in functionalizing the surface of nanoemulsions.

**Commercialized nanoemulsion products for the treatment of ocular diseases**

Novagali Pharma is a French ophthalmology-focused biopharmaceutical firm that was acquired by Santen Pharmaceutical in 2011. The formulation and development of ophthalmic products is the core area of expertise of this company. Its products are among some of the most popular ophthalmic products, and they are still improving their formulations using advanced and modified technologies.

Some important formulations of Novagali Pharma are Novasorb® and Catioprost® and Cationorm®, which are being used for treating glaucoma and have successfully entered clinical trial phases. Novasorb® is a cationic nanoemulsion containing latanoprost as an active pharmaceutical ingredient for treating glaucoma. It contains benzalkonium chloride as a cationic surfactant, which increases formulation adherence time with a negatively charged ocular surface and increases the formulation's effectiveness.

Formulation development encountered several challenges. One primary hurdle involved the careful selection of suitable cationic agents. Limited options existed because only a few cationic agents had official approval for use in ophthalmic formulations, given the potential risk of ocular toxicity and cell damage. The zeta potential emerged as a crucial parameter for stabilizing the formulation, imparted by these chosen cationic agents. Throughout the development process, it became evident that maintaining the zeta potential above +10 mV was vital for the stability of the nanoemulsion. To enhance stability, the zeta potential was optimized to fall within the range of +20 mV to +40 mV. The primary objective was to select the most appropriate cationic surfactant capable of providing a sufficiently high zeta potential at the lowest concentration while also aligning with regulatory standards.

Quaternary ammonium compounds have emerged as promising candidates, serving dual roles as preservatives and surfactants. Acting as preservatives, their positive charge allowed them to bind to the negatively charged surfaces of microorganisms, damaging their cell walls. However, it was noted that this positive charge also posed a potential risk of damaging ocular cells. The challenge was to strike a balance by selecting a cationic surfactant that effectively met both criteria.

Sznitowska discovered that the preservative action of...
quaternary ammonium compounds could be minimized by incorporating them into emulsions. In this context, most of their components become bound within the emulsion, reducing the presence of the free part in the aqueous phase and limiting its preservative action. Novagali Pharma adopted benzalkonium chloride and cetalkonium chloride (a lipophilic derivative of benzalkonium chloride) as innovative cationic nanovehicles.

The high lipophilic nature of Cetalkonium chloride’s facilitated its interaction with the oily phase, contributing to the high zeta potential of its droplets. This design minimized the amount of cetalkonium chloride available to induce ophthalmic toxicity. Studies indicated that buffering the formulation was unnecessary, as low-pH formulations were well tolerated by the eyes when quickly returned to normal ocular pH. Droplet size influences absorption, which occurs through diffusion. Various physicochemical characterization tests, including pH, zeta potential, surface tension, and interfacial tests, were conducted to assess formulation stability.

For drug loading, it is preferable to choose drug candidates that are nonionizable and lipophilic (with a log P value of 2 to 3) when preparing emulsions. Nanocarriers typically have a mechanism for active ingredient uptake, which can be explained in two ways:

A. When nanodroplets are intact and adhere to the mucin layer in close contact with corneal epithelial cells, they can enter the ocular cell membrane via two mechanisms: Active or passive diffusion, where nanodroplets release the active ingredients outside the cells.

B. When nanodroplets are in their intact form, they can be taken up by pinocytosis, phagocytosis, or endocytosis.

The use of benzalkonium chloride (BAK) in glaucoma eye solutions retains the solution over an extended period. However, it has also been demonstrated to cause and exacerbate the signs and symptoms of dry eye disease in patients. Cationic nanoemulsions, even without active ingredients, offer benefits for the eyes because of their basic composition, including oil, water, surfactants, and glycerol. This composition helps prevent tear evaporation, keeping the eyes lubricated and moisturized. As a result, a preservative-free and active ingredient-free emulsion has been globally commercialized to address dry eye symptoms.

Novasorb®, which contains benzalkonium chloride as a preservative, can induce signs and symptoms of dry eye disease. In contrast, Cationorm®, an artificial tear based on Novasorb®, can offer relief, particularly in cases of glaucoma-associated dry eye disease. Cationorm stands out among other artificial tears because it is preservative-free and contributes to the enhancement of the tear film’s condition through its unique composition. The positive charge on the oil droplets in Cationorm promotes adherence to the ocular surface, ensuring a prolonged duration of action. Its oil composition targets the lipid layer of the tear film, whereas the aqueous phase facilitates even distribution across the ocular surface, providing extended moisturization compared with other artificial tears. This mechanism effectively safeguards and nurtures the tear film.

Kinnunen et al conducted a study assessing the tolerability of Cationorm using in vitro testing on human corneal epithelial cells (HCE cells). The HCE cell culture line was used to evaluate the impact of Cationorm on cytotoxicity, cellular morphology, and inflammatory responses. The findings demonstrated its excellent tolerability compared with prior eye drops containing benzalkonium chloride.

Catioprost®, a cationic emulsion containing latanoprost as the active pharmaceutical ingredient, stands out because it is entirely free of the preservative benzalkonium chloride. It has been successfully compared with latanoprost-containing solutions containing benzalkonium chloride. The results indicated that both formulations were effective, with the benzalkonium chloride-free latanoprost cationic emulsion reducing conjunctival hyperemia by 42%. In addition, Catioprost® was found to be equally potent as Xalatan but with an enhanced safety profile. In comparison with benzalkonium chloride-free Travatan Z®, which contains travoprost in a 0.004% solution, Catioprost® demonstrated superior efficacy in reducing intraocular pressure and improving conditions related to ocular surface disease.

Emerging Nanoemulsion

Technologies for ocular delivery and patents granted in glaucoma field
Several nanoemulsions are available in the market not only for glaucoma but also for other ocular problems, as listed in Table 3.

Patents granted for ocular nanoemulsions
Table 4 lists the patents that have been granted to the ocular nanoemulsions that have been involved in treating glaucoma directly or indirectly.

Challenges and considerations concerning the formulation for developing ophthalmic nanoemulsions

Safety concerns and toxicity evaluation

Safety concerns
Because of their potential for better therapeutic efficacy and drug delivery, ophthalmic nanoemulsions intended for use in the eyes have drawn attention. However, when creating and applying ophthalmic nanoemulsions, particular safety issues must be considered. Some major safety issues with this formulation and related considerations are tabulated in Table S1 (Supplementary file 1).

Toxicity evaluation
The toxicological evaluation of ocular nanoemulsions entails a thorough examination of the potential side
Table 3. FDA-approved and under clinical trial nanoemulsions used for the delivery of medications at the ocular surface

<table>
<thead>
<tr>
<th>Marketed product</th>
<th>API</th>
<th>Targeted ocular disease</th>
<th>FDA approval/clinical trial phase</th>
<th>Manufacturer</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ikervis®</td>
<td>Cyclosporin A</td>
<td>Keratitis associated with dry eye disease</td>
<td>FDA approved</td>
<td>Santen</td>
<td>77</td>
</tr>
<tr>
<td>Restasis</td>
<td>Cyclosporin A</td>
<td>Chronic dry eye</td>
<td>FDA approved</td>
<td>Allergen</td>
<td>32</td>
</tr>
<tr>
<td>Durezol</td>
<td>difluprednate</td>
<td>Inflammation of eye</td>
<td>FDA approved</td>
<td>Alcon</td>
<td>78</td>
</tr>
<tr>
<td>Systane</td>
<td>Propylene glycol-based eye drop nanoemulsion</td>
<td>Dry eye treatment</td>
<td>Phase IV</td>
<td>Alcon</td>
<td>76</td>
</tr>
<tr>
<td>SVT-15473</td>
<td>Clobetasol propionate</td>
<td>Inflammation and pain in paediatric patients after cataract surgery</td>
<td>Phase III</td>
<td>Save laboratories</td>
<td>52</td>
</tr>
<tr>
<td>Cyclokat</td>
<td>Cyclosporin A</td>
<td>Dry eye</td>
<td>-</td>
<td>-</td>
<td>60</td>
</tr>
<tr>
<td>Verkazia</td>
<td>Cyclosporine</td>
<td>Vernal keratoconjunctivitis</td>
<td>FDA approved</td>
<td>Santen</td>
<td>80</td>
</tr>
<tr>
<td>SBI-100</td>
<td>Proprietary prodrug of tetrahydrocannabinol</td>
<td>Primary open-angle Glaucoma</td>
<td>Phase II</td>
<td>Skye Bioscience</td>
<td>81</td>
</tr>
<tr>
<td>-</td>
<td>Brimonidine Tartrate</td>
<td>Dry eye disease</td>
<td>Phase III</td>
<td>-</td>
<td>82</td>
</tr>
</tbody>
</table>

Table 4. List of patents in the last decade related to ocular nanoemulsions

<table>
<thead>
<tr>
<th>Patent No.</th>
<th>Patent Title</th>
<th>Publication date</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>CN116725954A</td>
<td>Nanometer medicinal preparation with antioxidant function and its use for treating glaucoma</td>
<td>12/09/2023</td>
<td>83</td>
</tr>
<tr>
<td>TW202247845A</td>
<td>Eye nanoemulsion composition containing prostaglandin derivative has better stability to provide convenience in the preservation</td>
<td>16/12/2022</td>
<td>84</td>
</tr>
<tr>
<td>CN115463088A</td>
<td>Ophthalmic nanoemulsion composition containing prostaglandin derivative</td>
<td>12/12/2022</td>
<td>85</td>
</tr>
<tr>
<td>US 20220125634 A1</td>
<td>Implantable ocular drug delivery devices and methods</td>
<td>28/04/2022</td>
<td>86</td>
</tr>
<tr>
<td>BR102014024497B1</td>
<td>Nanoemulsion compositions containing melaleuca leucadendron extract and/or fractions and use</td>
<td>23/11/2021</td>
<td>87</td>
</tr>
<tr>
<td>WO20201240376 A2</td>
<td>Ophthalmic nanoemulsion compositions</td>
<td>02/12/2021</td>
<td>88</td>
</tr>
<tr>
<td>WO2020240451A1</td>
<td>In situ gelling nanoemulsion of brinzolamide</td>
<td>03/12/2020</td>
<td>89</td>
</tr>
<tr>
<td>US20200197522A1</td>
<td>A pharmaceutical composition comprising brinzolamide</td>
<td>25/06/2020</td>
<td>90</td>
</tr>
<tr>
<td>US 20200315965A1</td>
<td>Nanoemulsion concentrate formulations and methods</td>
<td>08/10/2020</td>
<td>91</td>
</tr>
<tr>
<td>KR20200053205A</td>
<td>A surfactant-free type ophthalmic nano-emulsion composition, and the manufacturing method thereof</td>
<td>18/05/2020</td>
<td>92</td>
</tr>
<tr>
<td>BR102014024497A2</td>
<td>Nanoemulsified compositions of fructose leucadendron and/or pilocarpine extract and/or fractions and uses</td>
<td>21/11/2018</td>
<td>93</td>
</tr>
<tr>
<td>EP29784098B1</td>
<td>Ophthalmic composition, method for preparing the same, and use of the same</td>
<td>01/10/2018</td>
<td>94</td>
</tr>
<tr>
<td>US9801891B2</td>
<td>Compositions and methods for lowering intraocular pressure</td>
<td>31/10/2017</td>
<td>95</td>
</tr>
<tr>
<td>AU2010220321B2</td>
<td>Anionic oil-in-water emulsions containing prostaglandins and uses thereof</td>
<td>20/08/2015</td>
<td>96</td>
</tr>
<tr>
<td>JP57228038B2</td>
<td>Cationic oil-in-water emulsions containing prostaglandins and their use</td>
<td>27/05/2015</td>
<td>97</td>
</tr>
<tr>
<td>US8414904B2</td>
<td>Ophthalmic oil-in-water emulsions containing prostaglandins</td>
<td>9/04/2013</td>
<td>98</td>
</tr>
</tbody>
</table>

Effects and safety concerns associated with the use of these formulations in ophthalmic applications. The vital phases and concerns for toxicity assessment of ophthalmic nanoemulsions are summarized in Table S2 (Supplementary file 1).

**Potential side effects and mitigation strategies**

Owing to their unique formulation and administration method, ophthalmic nanoemulsions for eye application may have possible side effects. Ocular irritation, blurred vision, increased tear production, conjunctival hyperemia, photophobia, foreign body sensation, dry eye sensation, systemic absorption, corneal oedema, ocular discharge, corneal deposits, changes in IOP, visual disturbances, and allergic reactions are examples of these symptoms. 39,100 Ocular irritation can be modified by the choice of surfactants and excipients, and preclinical and clinical investigations should analyze the risk of irritation.

To reduce these side effects, formulation design, preclinical testing, and close monitoring during clinical trials is essential. 70 Throughout the development process, patient safety and ocular tolerability should be prioritized, and regulatory bodies should be involved to ensure the approval of safe and effective ophthalmic nanoemulsions. Regular intraocular pressure monitoring and adherence to regulatory criteria are critical for maintaining the
Choosing non-irritating

Glaucoma primarily stems from the hydrophobic, viscous polymer "poly(δ-decalactone)" destabilization mechanisms. For this purpose, the use of especially concerning surfactant choice, to counteract also gaining prominence. Stabilizing emulsions is essential, effects and increased bioavailability. In situ gelling systems adherence to the ocular surface to achieve longer-lasting prolonged use. Researchers have focused on improving is a growing trend to minimize ocular toxicity during removal of preservatives from nanoemulsion formulations Transcutol-P and Pluronic also gaining popularity. The as the surfactant for nanoemulsion development, with nanoemulsions offer convenience and versatility. plugs, implants, contact lenses, and fornix rings loaded with nanoemulsions offer convenience and versatility. However, they must be carefully constructed to achieve the desired functional characteristics.

In current ocular drug delivery trends, punctal plugs, implants, contact lenses, and fornix rings loaded with nanoemulsions offer convenience and versatility. Research predominantly favors the use of Tween 80 as the surfactant for nanoemulsion development, with Transcutol-P and Pluronic also gaining popularity. The removal of preservatives from nanoemulsion formulations is a growing trend to minimize ocular toxicity during prolonged use. Researchers have focused on improving adherence to the ocular surface to achieve longer-lasting effects and increased bioavailability. In situ gelling systems employing nanoemulsions as primary formulations are also gaining prominence. Stabilizing emulsions is essential, especially concerning surfactant choice, to counteract destabilization mechanisms. For this purpose, the use of the hydrophobic, viscous polymer "poly(δ-decalactone)" (PDL) is recommended. A combination of ionic and nonionic surfactants shows promise in facilitating the delivery of hydrophobic drugs. In addition, the selection of cationic agents is crucial for enhancing the adherence of nanoemulsions to the corneal epithelium.

Nanoemulsions have shown potential in various fields, including drug delivery, biomedical imaging, vaccine delivery, nutraceutical, cosmetics, agriculture, food and beverage industry, environmental remediation, antimicrobial applications, and regulatory guidelines. Interdisciplinary collaboration and advancements in nanotechnology will shape the future of nanoemulsion-based technologies, which require long-term safety and biocompatibility studies.

Interdisciplinary collaboration is vital for advancing nanoemulsion-based technologies, that span fields such as chemistry, biology, medicine, materials science, and engineering. These collaborations can lead to innovative solutions, breakthrough discoveries, and commercially viable products. Effective communication between experts from different disciplines can significantly enhance the progress of nanoemulsion-based technologies.

Concluding remarks

According to recent data from the World Health Organization (August 10, 2023), glaucoma affects approximately 7.7 million individuals out of 1 billion worldwide and ranks as the second leading cause of irreversible blindness. Glaucoma primarily stems from optic nerve damage due to elevated intraocular pressure and is often caused by hindrances in aqueous fluid outflow. Some patients with glaucoma exhibit normal or low blood pressure, possibly due to reduced ocular perfusion pressure from physiological changes or antihypertensive medication, contributing to optic nerve damage. Research continues to uncover unidentified factors related to glaucoma.

Artificial intelligence has played a crucial role in the diagnosis and management of glaucoma. For treatment, traditional and innovative drug delivery systems are available. Novel systems improve drug bioavailability by regulating intraocular pressure (10-21 mm Hg) and enhancing drug adherence to the ocular surface.

Many marketed nanoemulsion formulations are available for ophthalmic diseases such as dry eye disease and inflammation. Many research articles are available on nanoemulsion-based glaucoma treatment, however, very few nanoemulsions are available in the market for glaucoma. A notable gap in this field is the limited commercialization of patented research. The market availability of nanoemulsions designed for glaucoma treatment, particularly those employing nanoscale drug delivery systems, remains limited.

Acknowledgements

The authors from the Institute of Pharmacy, Bundelkhand University, Jhansi, India, express their gratitude to the
Review Highlights

✓ The existing literature on ophthalmic nanoemulsions has predominantly addressed barriers, challenges, preparation methods, and diverse applications of novel drug delivery systems for glaucoma.
✓ This research investigates the effectiveness of oil-in-water nanoemulsions in enhancing the bioavailability of hydrophobic drugs compared with conventional eye drops.
✓ This study compiles information on conducted research, granted patents, and the impact of nanoemulsions and nanoemulsion-based in-situ gels on glaucoma, encompassing safety concerns and toxicity evaluations. This article aims to consolidate this wealth of information into one comprehensive resource, with a specific emphasis on targeting nanoemulsions to the ocular surface for glaucoma treatment.

All authors declare that there are no conflicts of interest.

Competing Interests

Authors’ Contribution
Conceptualization Alok Kumar Mahor, Kuldeep Kumar Bansal.
Methodology Niraj Kumar Singh, Prem Prakash Singh, Priyanka Rathore.
Resources Prem Prakash Singh.
Supervision Alok Kumar Mahor.
Validation Niraj Kumar Singh.
Writing—original draft Ankita Kishore.
Writing—review editing Alok Kumar Mahor, Kuldeep Kumar Bansal.

Data Availability Statement
No data were used to support the findings of this study.

Ethical Statement
Not applicable.

Funding
This study received no funding.

Supplementary files
Supplementary file 1 contains Table S1 and S3.

References


